Application of farrerol and derivative thereof in preparation of ferroptosis inhibitor

By designing azalea derivatives to regulate the GSK-3β/Nrf2 axis, it enhances the inhibitory effect of ferrodystrophy on Erastin and RSL3-induced vascular endothelial cells, solves the bioavailability and toxicity of existing ferrodystrophyseal inhibitors, and provides new cardiovascular Disease treatment plan.

CN118994083AActive Publication Date: 2024-11-22SHANXI MEDICAL UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411078650.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

The existing ferrodysfunction inhibitors are not bioavailable and have high toxicity, making it difficult to effectively treat cardiovascular diseases.

Method used

A new class of azalea derivatives was designed and synthesized to enhance the inhibitory effect of Erastin and RSL3-induced ferrodemortosis of vascular endothelial cells by regulating the GSK-3β/Nrf2 axis on oxidative stress-induced vascular endothelial cells, and improve the Binding ability to GSK-3β.

Benefits of technology

It has achieved effective inhibition of iron mortality, provided new potential drugs for the treatment of cardiovascular diseases, has good medicinal potential and biological activity, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994083A_ABST
    Figure CN118994083A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of farrerol and derivatives thereof in preparation of ferroptosis inhibitors. The farrerol derivative disclosed by the invention has a structure as shown in a general formula (I). The invention proves that the derivative obtained by introducing a specific group to the R1 and R2 positions of the farrerol can generate a relatively good inhibition effect on ferroptosis of vascular endothelial cells, has a very good medicinal potential and is expected to become a novel candidate drug for preventing, improving or treating ferroptosis-related cardiovascular diseases; meanwhile, the preparation method of the novel compound is simple, convenient to operate and control, low in cost and suitable for industrial production, and the prepared compound is high in biological activity and remarkable in drug-likeness and has wide market prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and in particular to the application of rhododendrin and its derivatives in the preparation of ferroptosis inhibitors. Background Art

[0002] Cardiovascular disease is one of the major diseases that threaten human health. Vascular endothelial cells play an important role in maintaining and regulating cardiovascular function. Endothelial dysfunction is closely related to the occurrence and development of diseases such as atherosclerosis, hypertension, coronary artery disease, peripheral arterial disease, heart failure, diabetes and chronic renal failure.

[0003] Ferroptosis is an iron-dependent programmed cell death caused by lipid peroxidation. It is significantly different from apoptosis, programmed necrosis, pyroptosis, etc. Its typical morphological characteristics are increased density of mitochondrial double membrane, reduced volume, and reduced cristae. Recent studies have found that ferroptosis of vascular endothelial cells can lead to endothelial dysfunction characterized by reduced NO release, increased release of proinflammatory factors, increased vascular permeability, vasoconstriction, and abnormal angiogenesis. In addition, inhibiting endothelial cell ferroptosis can significantly improve endothelial dysfunction. It has been confirmed that ferroptosis inhibitors have therapeutic and alleviating effects on a variety of cardiovascular diseases such as atherosclerosis, diabetes, and heart failure. Therefore, ferroptosis inhibitors are considered to be potential drugs for the treatment of related diseases.

[0004] At present, ferroptosis inhibitors mainly include antioxidants, iron chelators, acyl-CoA synthetase long-chain family member 4 inhibitors, lipoxygenase inhibitors, etc., but they have shortcomings such as poor bioavailability and high toxicity. Therefore, the research and development of new ferroptosis inhibitors is urgently needed.

[0005] Using natural active ingredients as lead compounds for structural optimization is one of the important ways to develop new drugs. Rhododendron is a dihydroflavonoid compound derived from Rhododendron dasyphyllum, but the inhibitory effect of rhododendron on ferroptosis of vascular endothelial cells has not been reported. Summary of the invention

[0006] The present invention provides new uses of rhododendrin and its derivatives, provides the use of rhododendrin and its derivatives in the preparation of ferroptosis inhibitors, and provides a theoretical basis for the treatment of cardiovascular diseases related to vascular endothelial dysfunction with ferroptosis as the target.

[0007] To achieve the above objectives, the specific technical solutions of the present invention are as follows.

[0008] The object of the present invention is to provide a rhododendron derivative having a structure as shown in the general formula (I):

[0009]

[0010] Wherein R1 is selected from Any of the following;

[0011] R2 is selected from Any one of; n is an integer from 1 to 8.

[0012] The preliminary study of the present invention found that rhododendrin plays a protective role on vascular endothelial cells damaged by oxidative stress by regulating the GSK-3β / Nrf2 (an important regulator of ferroptosis) axis. The present invention found that rhododendrin has an inhibitory effect on vascular endothelial cell ferroptosis induced by Erastin and RSL3, respectively. Molecular docking simulation shows that when rhododendrin is present in the ATP binding site of GSK-3β, there is an unoccupied cavity at R′ in formula (II), which can be used for the structural optimization of such compounds. Therefore, with rhododendrin as the lead compound and GSK-3β as the target, a series of novel rhododendrin derivatives were designed by computer-aided drug design methods by changing the position of the substituent on R′ in formula (II) (ortho, meta and para); the type of the substituent (N-methylpiperazinyl, dimethylamino, pyrrolyl, piperidinyl, morpholinyl and phenyl); the number of carbon atoms connected to the parent nucleus (2 or 3) to enhance the binding ability of such compounds with GSK-3β and ultimately enhance their ferroptosis inhibitory activity. The structure-activity relationship shows that substitutions at the ortho and para positions can enhance the inhibitory activity of ferroptosis in vascular endothelial cells. The types of substituents that can enhance the activity include: benzene ring, dimethylamino, piperidine, and pyrrolyl.

[0013]

[0014] In some technical solutions of the present invention, the structure of the rhododendronine derivative is one of the following compounds:

[0015]

[0016]

[0017] Another object of the present invention is to provide a method for preparing the rhododendron derivative, comprising: adding intermediate 3, intermediate 4, boric acid, L-proline and magnesium oxide to glycerol, mixing and heating to 115° C. for reaction, obtaining a reaction product after the reaction is completed, and separating and purifying the reaction product to obtain the rhododendron derivative;

[0018] The structural formula of the intermediate 3 is as follows:

[0019]

[0020] The general structural formula of the intermediate 4 is as follows:

[0021]

[0022] Wherein R3 is selected from Any of the following;

[0023] R4 is selected from Any one of; n is 2 or 3.

[0024] In some embodiments of the present invention, the molar ratio of the intermediate 3, the intermediate 4, boric acid, L-proline and the magnesium oxide solution is 0.5-1.5:3.5-4.5:2.5-3.5:0.5-1.5:1.5-2.5; and the volume of the glycerol is 0.5-1.5 mL.

[0025] In some embodiments of the present invention, the reaction time is 3-7 hours.

[0026] In some embodiments of the present invention, separation and purification includes: using ethanol to dissolve the reaction product, then adding silica gel to mix the sample, then drying under reduced pressure, silica gel column chromatography, and then eluting with an eluent to obtain a liquid, and the liquid is dried under reduced pressure to obtain a solid powder, that is, a rhododendron derivative.

[0027] Another object of the present invention is to provide the use of rhododendrin or rhododendrin structural analogs in the preparation of vascular endothelial cell ferroptosis inhibitors, wherein the rhododendrin structural analogs include: the rhododendrin derivatives and stereoisomers of the rhododendrin derivatives.

[0028] Another object of the present invention is the use of rhododendrin or rhododendrin structural analogs in the preparation of drugs for preventing or treating ferroptosis-related cardiovascular diseases, wherein the rhododendrin structural analogs include: the rhododendrin derivatives and stereoisomers of the rhododendrin derivatives.

[0029] In some embodiments of the present invention, the ferroptosis-related cardiovascular diseases include: atherosclerosis, hypertension, coronary artery disease, peripheral arterial disease, heart failure, diabetes and chronic renal failure.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] The present invention designs and synthesizes a novel dihydroflavonoid rhododendrin derivative, which can have a good inhibitory effect on ferroptosis, and provides a theoretical basis for the treatment of cardiovascular diseases related to vascular endothelial dysfunction with ferroptosis as the target. The derivative has good medicinal potential and can be used as the main active ingredient for preparing ferroptosis inhibitors. At the same time, the preparation method of the new compound provided by the present invention is simple, easy to operate and control, low in cost, suitable for industrial production, and the prepared compound has high biological activity, significant drug-like properties, and broad market prospects.

[0032] The applicant of the present invention has found in previous research that rhododendrin can not only protect vascular endothelial cells damaged by oxidative stress by regulating Nrf2, an important regulatory factor of ferroptosis, but also inhibit ferroptosis of vascular endothelial cells induced by Erastin and RSL3, respectively. Therefore, using rhododendrin as a lead compound for chemical structure modification has important research significance for the development of new ferroptosis inhibitors with high inhibitory activity and can be used to treat cardiovascular diseases related to vascular endothelial dysfunction. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 : is a graph showing the protective effect of rhododendron and rhododendron derivatives on the HUVEC cell ferroptosis model induced by Erastin and RSL3 in the present invention; wherein, Figure 1 A represents the results of the determination of the protective effects of rhododendron and rhododendron derivatives on the erastin-induced HUVEC cell ferroptosis model;

[0034] Figure 1 B is the protective effect of rhododendronine and rhododendronine derivatives on RSL3-induced HUVEC cell ferroptosis model.

[0035] Figure 2 It is a line graph showing that the rhododendrin derivative G3 of the present invention inhibits Erastin-induced ferroptosis in HUVEC cells.

[0036] Figure 3 It is a line graph showing that the rhododendrin derivative G3 of the present invention inhibits RSL3-induced ferroptosis in HUVEC cells. DETAILED DESCRIPTION

[0037] The present invention is described in detail below in conjunction with specific examples, but it should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0038] In the following preparation examples, 1 H-NMR and 13 C-NMR was measured using a Bruker Avance III HD 600 NMR spectrometer. MS was measured using a Bruker impact HD mass spectrometer. The anhydrous solvents used were obtained by drying according to standard methods. Unless otherwise specified, all reactions were tracked by TLC. The products were purified by column chromatography using silica gel (200-300 mesh) unless otherwise specified.

[0039] Example 1 Synthesis of target compound

[0040] Preparation method step 1: Synthesis of intermediate 1

[0041] The synthetic route is as follows:

[0042]

[0043] Prepare a mixed solution of concentrated nitric acid (2.3 mL) and concentrated sulfuric acid (5.0 mL) under ice bath conditions. Then add 2.4 mL of m-xylene in batches at 40°C, react for 5 minutes after the addition is complete, cool, remove the aqueous phase after the reaction is separated, and add concentrated sulfuric acid (6.6 mL) and concentrated nitric acid (2.5 mL) again. React at 40°C for 5 minutes, then heat to 115°C and react for 3 hours. After the reaction is completed, remove the aqueous phase, wash the product with sodium carbonate solution, and filter it with suction. The obtained white solid is intermediate 1.

[0044] Preparation method step 2: Synthesis of intermediate 2

[0045] The synthetic route is as follows:

[0046]

[0047] Add intermediate 1 (2.2 g) to 23 mL of concentrated hydrochloric acid, and add 8.8 g of tin powder at 45 ° C. Then heat to 120 ° C for reaction, and monitor the reaction progress by TLC. After the reaction is completed, adjust the pH of the reaction solution to 4 with 40% sodium hydroxide solution and continue to heat and reflux for 24 hours. After the reflux is completed, collect the filtrate by suction filtration, and wash the precipitate with hot water 3 times. Combine the filtrate and the washing liquid, extract with ethyl acetate, dry overnight with anhydrous sodium sulfate, filter, and dry under reduced pressure to obtain intermediate 2.

[0048] Preparation method step 3: Synthesis of intermediate 3

[0049] The synthetic route is as follows:

[0050]

[0051] Dissolve intermediate 2 (1 g) and anhydrous zinc chloride (1.8 g) in 30 mL of anhydrous acetonitrile. In an ice bath, pass dry hydrogen chloride gas into the solution until a large amount of yellow-white solid precipitates. Seal the reaction bottle and place it at 4°C overnight, and filter to obtain a milky white solid. Add water to dissolve the obtained solid, heat to reflux for 2 hours, filter, and vacuum dry to obtain intermediate 3.

[0052] Preparation method step 4: General synthesis method of intermediate 4 (etherification)

[0053] Intermediate 4 is prepared by aldehyde-ketone condensation reaction and high temperature boric acid method, which specifically includes: 2mmol of hydroxybenzaldehyde, 2mmol of chlorinated product, 1.8g of anhydrous tin chloride, 829mg of anhydrous potassium carbonate (6mmol) and 2mg of potassium iodide (catalyst) are placed in a 50ml eggplant-shaped bottle, 30ml of chromatographic acetonitrile is added, heated to reflux for 48h, and the reaction is monitored by TLC. After the reaction is completed, the filtrate is filtered, silica gel is added to the filtrate, the sample is mixed, and the sample is dried by spin drying. The intermediate 4 is obtained by silica gel column chromatography. The reaction formula is as follows:

[0054]

[0055] Wherein R3 is selected from Any of the following;

[0056] R4 is selected from Any one of; n is 2 or 3.

[0057] Preparation method step 5: General method for the synthesis of target compound

[0058] At 80°C, add intermediate 3 (1mmol), intermediate 4 (1mmol), boric acid (3mmol), L-proline (1mmol) and magnesium oxide (2mmol) to 1mL glycerol, mix thoroughly and heat to 115°C for 3-7h, and monitor the reaction using TLC. After the reaction is completed, add anhydrous ethanol and dissolve it by ultrasound, add 1g silica gel to mix the sample, the ratio of anhydrous ethanol to silica gel is 20mL:1g, and dry under reduced pressure at 45°C. After silica gel column chromatography, use an eluent to elute and separate to obtain a liquid. After separation, dry under reduced pressure to obtain a solid powder, and obtain the target compound (rhododendron derivative). The general reaction formula is as follows:

[0059]

[0060] Specifically, the synthesis of each target compound is as follows:

[0061] (1) During the synthesis of compound A1, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0062] The chemical formula of compound A1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0063]

[0064] Yellow solid, yield: 22%; mp: 181-182°C;1 H-NMR (600MHz, CDCl3) δ12.25 (s, 1H), 7.32 (t, J = 8.2Hz, 1H), 7.03–6.98 (m, 2H), 6.91–6.87(m,1H),5.37(ddd,J=15.3,11.0,3.9Hz,1H),4.04(t,J=6.3Hz,2H),3. 02(dd,J=17.1,12.3Hz,1H),2.86(dd,J=17.1,3.2Hz,1H),2.57(dq,J=20.1,12.4 ,10.3Hz,10H),2.33(s,3H),2.08(d,J=5.5Hz,6H),1.98(dt,J=13.5,6.4Hz,2H); 13 C-NMR(151MHz,DMSO-d6)δ196.71,163.31,159.21,158.90,157.52,141.21,130.14,118.69,114.66,112.9 0,103.87,103.12,102.09,78.21,66.33,55.13,54.81,53.07,46.06,42.60,26.64,8.76,8.08;MS(ESI)m / z 441.31([M+H] + ).

[0065] (2) During the synthesis of compound A2, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 25:1, and the remaining steps are carried out with reference to the general method for synthesizing the target compound in step 5.

[0066] The chemical formula of compound A2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0067]

[0068] Yellow solid, yield: 29%; mp: 174-175°C; 1H-NMR (600MHz, CDCl3) δ12.28(s,1H,5-OH),7.37(d,J=8.6Hz,2H),6.94(d,J=8.7Hz,2H),5.34(dd,J=12.8,2.9Hz,1H),4.04(t,J=6.3Hz,2H),3. 05(dd,J=17.0,12.8Hz,1H),2.81(dd,J=17.0,3.0Hz,1H),2.73–2.34(m, 10H),2.30(s,3H),2.06(d,J=14.9Hz,6H),1.98(dt,J=13.6,6.5Hz,2H); 13 C-NMR (151MHz, DMSO) δ197.01,163.24,159.13,158.89,157.73,131.45,128.31,114.87,103.77,103.05, 102.10,78.18,66.35,55.13,54.80,53.05,46.05,42.48,26.66,8.73,8.07; MS(ESI)m / z439.38([MH]-).

[0069] (3) During the synthesis of compound A3, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 25:1, and the remaining steps are carried out with reference to the general method for synthesizing the target compound in step 5.

[0070] The chemical formula of compound A3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0071]

[0072] Yellow solid, yield: 18%; mp: 75-76°C; 1H-NMR (600MHz, CDCl3) δ12.31(s,1H),7.61(dd,J=7.6,1.3Hz,1H),7.32(td,J=8 .3,1.6Hz,1H),7.06–7.02(m,1H),6.92(d,J=8.1Hz,1H),5.70(dd,J=11.5,4.5H z,1H),4.09–4.02(m,2H),2.93–2.89(m,1H),2.89–2.84(m,1H),2.49(q,J=20.1 ,10.3Hz,10H),2.29(s,3H),2.07(d,J=4.9Hz,6H),1.97(dt,J=13.5,6.3Hz,2H); 13 C-NMR(151MHz,DMSO-d6)δ197.03,163.23,158.91,157.99,155.83,129.98,127.59,126.86,121.00,112.5 8,103.84,103.09,101.97,74.16,66.62,55.06,54.85,53.00,46.01,41.74,26.60,8.73,8.07; MS(ESI)m / z 439.82([MH]-).

[0073] (4) During the synthesis of compound B1, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0074] The chemical formula of compound B1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0075]

[0076] Yellow solid, yield: 32%; mp: 171-172°C; 1H-NMR(600MHz,DMSO-d6)δ12.37(s,1H),7.32(t,J=8.1Hz,1H),7.09–7.04(m ,2H),6.92(dd,J=8.2,2.1Hz,1H),5.50(dd,J=12.1,3.1Hz,1H),4.02(t,J=6 .4Hz,2H),3.16(dd,J=17.0,12.2Hz,1H),2.83(dd,J=17.0,3.2Hz,1H),2.43 (t,J=7.2Hz,2H),2.20(s,6H),1.97(d,J=10.1Hz,6H),1.87(p,J=6.7Hz,2H); 13 C-NMR(151MHz,DMSO-d6)δ196.61,163.53,159.18,158.91,157.51,141.24,130.14,118.72,114.61 ,112.90,103.89,103.14,102.02,78.21,66.19,56.00,45.37,42.61,27.07,8.76,8.09;MS(ESI)m / z 386.21([M+H] + ).

[0077] (5) During the synthesis of compound B2, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 20:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0078] The chemical formula of compound B2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0079]

[0080] Yellow solid, yield: 30%; mp: 120-121°C; 1 H-NMR (600MHz, DMSO-d6) δ12.38(s,1H),7.46(d,J=8.6Hz,2H),7.00(d,J=8.7Hz,2H),5.50(dd,J=12.1,2.9Hz,1H),4.08 (t,J=5.9Hz,2H),3.24–3.19(m,3H),2.82(s,6H),2.80–2.77(m,1H),2.10(dq,J=12.2,6.1Hz,2H),1.95(d,J=7.0Hz,6H); 13C-NMR(151MHz,DMSO-d6)δ197.17,162.90,158.87,158.69,157.69,131.86,128.36,114.95 ,103.75,103.01,102.21,78.12,65.27,54.83,42.97,42.45,24.51,8.73,8.08;MS(ESI)m / z 386.42([M+H] + ).

[0081] (6) During the synthesis of compound B3, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0082] The chemical formula of compound B3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0083]

[0084] Yellow solid, yield: 35%; mp: 158-159°C; 1 H-NMR(600MHz,DMSO-d6)δ12.36(s,1H),7.54(d,J=6.8Hz,1H),7.37–7.31 (m,1H),7.07–7.01(m,2H),5.67(dd,J=12.8,2.8Hz,1H),4.04(tt,J=9.5,4 .6Hz,2H),3.09(dd,J=17.0,12.8Hz,1H),2.77(dd,J=17.0,3.0Hz,1H),2.3 9(tt,J=11.8,6.2Hz,2H),2.14(s,6H),1.97(s,6H),1.86(p,J=6.7Hz,2H); 13 C-NMR(151MHz,DMSO-d6)δ196.85,163.55,158.93,157.96,155.77,129.93,127.63,126.82,120.98 ,112.47,103.86,103.13,101.86,74.14,66.47,56.09,45.39,41.77,27.10,8.74,8.09;MS(ESI)m / z 386.13([M+H] + ).

[0085] (7) During the synthesis of compound C1, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 25:1, and the remaining steps are carried out with reference to the general method for synthesizing the target compound in step 5.

[0086] The chemical formula of compound C1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0087]

[0088] Yellow solid, yield: 25%; mp: 81-82°C; 1 H-NMR (600MHz, CDCl3) δ12.27(s,1H),7.29(t,J=8.1Hz,1H),6.99(dd,J=4.1,2.3 Hz, 2H), 6.85 (dd, J=8.1, 1.8Hz, 1H), 5.33 (dd, J=12.3, 3.1Hz, 1H), 4.03 (td, J=6. 2,1.9Hz,2H),2.98(dd,J=17.0,12.3Hz,1H),2.85–2.82(m,1H),2.79(dd,J=8.1, 5.4Hz,2H),2.73(s,4H),2.06(d,J=1.8Hz,8H),1.87(dq,J=9.6,6.1,4.8Hz,4H); 13 C-NMR (151MHz, CDCl3) δ195.78,159.31,159.06,157.41,140.73,129.81,118.13,114.27,112.11, 104.20,103.22,102.45,78.29,66.02,54.11,53.12,43.33,28.07,23.38,8.07,7.30; MS(ESI)m / z 410.57([MH]-).

[0089] (8) During the synthesis of compound C2, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0090] The chemical formula of compound C2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0091]

[0092] Yellow solid, yield: 25%; mp: 162-163°C; 1 H-NMR (600MHz, DMSO-d6) δ12.37(s,1H),9.85(s,1H),7.45(d,J=8.6Hz,2H),6.99(d,J=8.7Hz,2H ),5.49(dd,J=12.1,2.8Hz,1H),4.08(t,J=6.0Hz,2H),3.65–3.54(m,2H),3.34–3.26(m,2H),3.2 0(dd,J=17.0,12.2Hz,1H),3.04(dq,J=14.1,6.9Hz,2H),2.80(dd,J=17.0,3.1Hz,1H),2.16–2.0 7(m,2H),2.02(dq,J=12.4,6.7,4.7Hz,2H),1.95(d,J=6.1Hz,6H),1.87(dt,J=14.8,7.4Hz,2H); 13 C-NMR (151MHz, DMSO) δ197.15,162.94,158.88,158.69,157.69,131.87,128.34,114.95,103. 79,103.05,102.21,78.11,65.23,53.80,51.91,42.45,25.79,23.08,8.70,8.05; MS(ESI)m / z 410.76([MH]-).

[0093] (9) During the synthesis of compound C3, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 40:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0094] The chemical formula of compound C3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0095]

[0096] Yellow solid, yield: 30%; mp: 110-111°C; 1H-NMR(600MHz, CDCl3)δ12.24(s,1H),7.63–7.56(m,1H),7.37–7.30(m,1H),7.07( t,J=7.5Hz,1H),6.90(d,J=8.2Hz,1H),5.62(dd,J=13.1,2.7Hz,1H),4.12(t,J=5.7 Hz,2H),3.09(t,J=7.7Hz,6H),2.94(dd,J=17.0,13.1Hz,1H),2.82(dd,J=17.0,2.9 Hz,1H),2.32(dt,J=13.4,6.4Hz,2H),2.08(d,J=2.8Hz,6H),2.04(t,J=7.6Hz,4H); 13 C-NMR (151MHz, CDCl3) δ196.90,161.69,159.23,157.96,154.73,129.57,127.38,126.49,121.43,111 .44,103.54,102.55,102.51,74.42,65.27,53.99,53.20,42.41,26.55,23.36,8.02,7.21; MS(ESI)m / z 410.52([MH]-).

[0097] (10) During the synthesis of compound D1, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0098] The chemical formula of compound D1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0099]

[0100] Yellow solid, yield: 72%; mp: 131-132°C; 1H-NMR (600MHz, DMSO-d6) δ12.37(s,1H),7.32(t,J=8.1Hz,1H),7.06(d,J=6.5Hz,2H),6. 91(dd,J=8.2,1.7Hz,1H),5.49(dd,J=12.1,3.1Hz,1H,4.01(d,J=12.8Hz,2H),3.14(dd, J=17.0,12.1Hz,1H),2.83(dd,J=17.0,3.2Hz,1H),2.43(t,J=7.2Hz,2H),2.38(s,4H),1 .97(s,3H),1.96(s,3H),1.88(p,J=6.6Hz,2H),1.50(p,J=5.5Hz,4H),1.42–1.34(m,2H); 13 C-NMR(151MHz,DMSO-d6)δ196.44,163.80,159.20,158.93,157.49,141.27,130.12,118.68,114.62,112.90,103.9 1,103.17,101.95,78.18,66.38,55.49,54.44,42.61,26.56,25.86,24.42,8.76,8.10; MS(ESI)m / z424.31([MH]-).

[0101] (11) During the synthesis of compound D2, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0102] The chemical formula of compound D2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0103]

[0104] Yellow solid, yield: 35%; mp: 186-187°C; 1H-NMR (600MHz, DMSO-d6) δ12.37(s,1H),7.44(d,J=8.7Hz,2H),6.98(d,J=8.7Hz,2H),5.48(dd,J=12.2,3.0Hz,1H),4.05(t,J=6.1Hz,2H,3.20(dd ,J=17.0,12.3Hz,1H),3.01–2.81(m,6H),2.79(dd,J=17.0,3.1Hz,1H),2 .11–2.03(m,2H),1.95(d,J=6.6Hz,6H),1.72–1.64(m,4H),1.49(s,2H); 13 C-NMR(151MHz,DMSO-d6)δ197.13,163.01,158.93,158.88,157.77,131.65,128.33,114.92,103.78,103.0 5,102.18,78.16,65.97,54.64,53.45,42.47,25.12,24.31,23.08,8.74,8.08; MS(ESI)m / z424.38([MH]-).

[0105] (12) During the synthesis of compound D3, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 36:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0106] The chemical formula of compound D3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0107]

[0108] Yellow solid, yield: 45%; mp: 82.7-84°C; 1H-NMR(600MHz,DMSO-d6)δ12.36(s,1H),7.53(d,J=7.3Hz,1H),7.37–7.30(m,1H),7.0 9–6.99(m,2H),5.66(dd,J=12.8,2.8Hz,1H),4.03(tt,J=9.5,4.6Hz,2H),3.10(dd,J=1 7.0,12.8Hz,1H),2.75(dd,J=17.0,2.9Hz,1H),2.38(t,J=7.2Hz,2H),2.29(s,4H),1.9 7(s,3H),1.96(s,3H),1.86(p,J=6.4Hz,2H),1.45(p,J=5.5Hz,4H),1.37–1.31(m,2H); 13 C-NMR(151MHz,DMSO-d6)δ196.77,163.68,158.94,157.96,155.84,129.94,127.63,126.87,120.96,112.53,103.8 5,103.13,101.82,74.16,66.64,55.55,54.43,41.73,26.60,25.91,24.47,8.75,8.08; MS(ESI)m / z424.25([MH]-).

[0109] (13) During the synthesis of compound E1, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 50:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0110] The chemical formula of compound E1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0111]

[0112] Yellow solid, yield: 50%; mp: 182-183°C; 1H-NMR (600MHz, DMSO-d6) δ12.37(s,1H),9.76(s,1H),7.33(t,J=8.1Hz,1H),7.07( m,2H),6.93(d,J=8.3Hz,1H),5.52(dd,J=12.1,3.2Hz,1H),4.03(t,J=6.4Hz,2H),3 .57(t,J=4.6Hz,4H),3.19(dd,J=17.1,12.2Hz,1H),2.85(dd,J=17.1,3.3Hz,1H),2 .43(t,J=7.2Hz,2H),2.38(s,4H),1.98(s,3H),1.96(s,3H),1.88(q,J=6.8Hz,2H); 13 C-NMR(151MHz,DMSO-d6)δ196.87,162.98,159.20,158.90,157.54,141.18,130.14,118.71,114.65,11 2.92,103.87,103.09,102.20,78.24,66.63,66.28,55.30,53.81,42.61,26.29,8.72,8.05; MS(ESI)m / z 426.26([MH]-).

[0113] (14) During the synthesis of compound E2, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 60:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0114] The chemical formula of compound E2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0115]

[0116] Yellow solid, yield: 50%; mp: 132-133°C; 1H-NMR (600MHz, DMSO-d6) δ12.37 (s, 1H), 7.42 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8. 6Hz,2H),5.46(dd,J=12.3,3.0Hz,1H),4.02(t,J=6.3Hz,2H),3.57(t,J=4.5 Hz,4H),3.18(dd,J=17.0,12.3Hz,1H),2.78(dd,J=17.0,3.1Hz,1H),2.43(t ,J=7.2Hz,2H),2.38(s,4H),1.96(s,3H),1.95(s,3H),1.88(p,J=6.6Hz,2H); 13 C-NMR(151MHz,DMSO-d6)δ197.15,162.93,159.13,158.89,157.75,131.45,128.30,114.88,103.77,1 03.02,102.20,78.20,66.64,66.30,55.28,53.81,42.49,26.31,8.71,8.05; MS(ESI)m / z428.17([M+H] + ).

[0117] (15) During the synthesis of compound E3, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 50:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0118] The chemical formula of compound E3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0119]

[0120] Yellow solid, yield: 65%; mp: 185-186°C; 1 H-NMR (600MHz, DMSO-d6) δ12.35(s,1H),9.76(s,1H),7.54(s,1H),7.36(s,1H),7.05(d,J=20.2Hz,2H),5.67(d,J=9.2Hz,1H),4.06 (s,2H),3.53(s,4H),3.12(d,J=11.9Hz,1H),2.77(d,J=14.9Hz,1H),2.41(s,2H),2.31(s,4H),1.97(s,6H),1.21(d,J=34.1Hz,2H);13 C-NMR(151MHz,DMSO-d6)δ197.16,162.94,158.90,158.00,155.81,129.97,127.57,126.84,121.00,11 2.55,103.84,103.07,102.06,74.20,66.59,66.53,55.32,53.77,41.75,26.26,8.71,8.05; MS(ESI)m / z 426.27([MH] - ).

[0121] (16) During the synthesis of compound F1, R3 in intermediate 4 is R4 is independent n=2, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0122] The chemical formula of compound F1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0123]

[0124] Yellow solid, yield: 33%; mp: 115-116°C; 1 H-NMR (600MHz, DMSO-d6) δ12.36(s,1H),7.33(t,J=7.9Hz,1H),7.08(d,J=8.0Hz, 2H),6.94(dd,J=8.3,1.9Hz,1H),5.51(dd,J=12.1,3.1Hz,1H),4.09(t,J=5.9Hz,2 H),3.17(dd,J=17.0,12.2Hz,1H),2.84(dd,J=17.0,3.2Hz,1H),2.68(t,J=5.9Hz, 2H),2.46(s,4H),1.97(d,J=9.7Hz,6H),1.50(p,J=5.6Hz,4H),1.41–1.36(m,2H); 13C-NMR(151MHz,DMSO-d6)δ196.81,163.16,159.04,158.90,157.54,141.20,130.14,118.80,114.72,11 2.96,103.86,103.10,102.14,78.24,65.94,57.70,54.81,42.61,25.91,24.28,8.74,8.07; MS(ESI)m / z 410.31([MH]-).

[0125] (17) During the synthesis of compound F2, R3 in intermediate 4 is R4 is independent n=2, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 30:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0126] The chemical formula of compound F2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0127]

[0128] Yellow solid, yield: 25%; mp: 180-181°C; 1 H-NMR (600MHz, DMSO-d6) δ12.38(s,1H),7.43(d,J=8.7Hz,2H),6.98(d,J=8.7Hz,2H),5.47(dd,J=12.3,3.0Hz,1H),4.08(t,J=5.9Hz,2H),3.20(dd,J =17.0,12.3Hz,1H),2.78(dd,J=17.0,3.1Hz,1H),2.68(t,J=5.9Hz,2H),2. 45(s,4H),1.95(d,J=7.1Hz,6H),1.50(p,J=5.6Hz,4H),1.41–1.35(m,2H); 13 C-NMR (151MHz, DMSO-d6δ197.10,163.08,158.97,158.89,157.73,131.53,128.32,114.93,103.75,1 03.03,102.15,78.18,66.02,57.72,54.81,42.47,25.94,24.31,8.73,8.07; MS(ESI)m / z410.49([MH] - ).

[0129] (18) During the synthesis of compound F3, R3 in intermediate 4 is R4 is independent n=2, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 36:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0130] The chemical formula of compound F3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0131]

[0132] Yellow solid, yield: 30%; mp: 201-202°C; 1 H-NMR (600MHz, DMSO-d6) δ12.38(s,1H),7.63–7.49(m,1H),7.36(s,1H),7.08(dd,J=26.3,6.4Hz,2H),5.71(d,J=12.1Hz,1H),4.31– 4.14(m,2H),3.17–3.10(m,1H),2.86(d,J=15.2Hz,2H),2.82(s,1H),2.73–2.53(m,4H),1.97(s,6H),1.52(s,4H),1.42–1.34(m,2H); 13 C-NMR(151MHz,DMSO-d6)δ197.27,162.90,158.91,158.03,155.79,141.85,130.03,128.74,127.43,126.93,126.26, 120.96,112.34,103.81,103.06,102.12,74.17,67.43,41.72,,32.12,30.92,8.73,8.08; MS(ESI)m / z410.54([MH]-).

[0133] (19) During the synthesis of compound G1, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 18:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0134] The chemical formula of compound G1, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0135]

[0136] Yellow solid, yield: 35%; mp: 158-159°C; 1 H-NMR (600MHz, DMSO-d6) δ12.36(s,1H),9.68(s,1H),7.33(t,J=8.0Hz,1H),7.28(t,J=7.5H z,2H),7.23(d,J=7.3Hz,2H),7.19(d,J=7.5Hz,1H),7.08(d,J=6.9Hz,2H),6.95–6.90(m,1H ),5.51(dd,J=12.1,2.8Hz,1H),3.99(t,J=6.3Hz,2H),3.17(dd,J=17.0,12.2Hz,1H),2.85( dd,J=17.0,3.0Hz,1H),2.75(t,J=7.6Hz,2H),2.06–2.00(m,2H),1.98(s,3H),1.97(s,3H); 13 C-NMR(151MHz,DMSO-d6)δ196.92,162.95,159.19,158.90,157.56,141.83,141.20,130.16,128.78,126.29, 118.75,114.67,112.96,103.88,103.10,102.22,78.24,67.21,42.61,31.96,30.81,8.73,8.06; MS(ESI)m / z 417.24([MH]-).

[0137] (20) During the synthesis of compound G2, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 12:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0138] The chemical formula of compound G2, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0139]

[0140] Yellow solid, yield: 34%; mp: 140-141°C; 1H-NMR (600MHz, DMSO-d6) δ12.39(s,1H),9.68(s,1H),7.43(d,J=8.5Hz,2H),7.29(t,J =7.4Hz,2H),7.24(d,J=7.3Hz,2H),7.19(t,J=7.1Hz,1H),6.98(d,J=8.5Hz,2H),5.47 (dd,J=12.3,2.6Hz,1H),3.98(t,J=6.2Hz,2H),3.21(dd,J=17.0,12.5Hz,1H),2.78(d d,J=17.1,2.8Hz,1H),2.76–2.71(m,2H),2.04–2.00(m,2H),1.96(s,3H),1.95(s,3H); 13 C-NMR(151MHz,DMSO-d6)δ197.22,162.93,159.11,158.88,157.76,141.82,131.47,128.81,128.35, 126.30,114.87,103.74,103.01,102.19,78.21,67.19,42.47,31.94,30.83,8.74,8.07; MS(ESI)m / z 417.69([MH]-).

[0141] (21) During the synthesis of compound G3, R3 in intermediate 4 is R4 is independent n=3, the eluent is a mixed solution of dichloromethane and methanol in a volume ratio of 20:1, and the remaining steps are carried out with reference to step 5, the general method for synthesizing the target compound.

[0142] The chemical formula of G3, 1 H-NMR, 13 C-NMR and MS data are as follows:

[0143]

[0144] Yellow solid, yield: 30%; mp: 166-167°C; 1H-NMR(600MHz,DMSO-d6)δ12.37(s,1H),9.71(s,1H),7.54(d,J=7.1Hz,1H),7.36–7.31 (m,1H),7.23(t,J=7.5Hz,2H),7.17–7.12(m,3H),7.03(t,J=7.6Hz,2H),5.65(dd,J=12. 9,2.8Hz,1H),4.02(tt,J=9.4,4.7Hz,2H),3.16(dd,J=17.0,12.9Hz,1H),2.80(dd,J=1 7.0,2.9Hz,1H),2.72(h,J=6.3Hz,2H),2.03(q,J=6.7Hz,2H),1.98(s,3H),1.97(s,3H); 13 C-NMR(151MHz,DMSO-d6)δ197.27,162.90,158.91,158.03,155.79,141.85,130.03,128.74,127.43,126.93,126.26, 120.96,112.33,103.81,103.05,102.12,74.17,67.43,41.72,32.12,30.92,8.73,8.08; MS(ESI)m / z417.31([MH]-).

[0145] Example 2 Inhibitory activity of the compounds of the present invention on ferroptosis of HUVEC vascular endothelial cells

[0146] 1. Experimental materials:

[0147] Cell line: HUVEC human umbilical vein endothelial cells were purchased from Zhejiang Meisen Cell Technology Co., Ltd.

[0148] The ferroptosis inducer Erastin was purchased from Aladdin, RSL3 was purchased from MCE, rhododendron standard was purchased from China Food and Drug Administration, MTT was purchased from Solebao, and ECM culture medium, fetal bovine serum and double antibody were purchased from Siencell.

[0149] Test samples: the compound synthesized in Example 1 of the present invention (rhododendronine derivative) and rhododendronine.

[0150] 2. Experimental methods

[0151] HUVEC cell culture conditions: ECM culture medium + 5% fetal bovine serum + 1% primary endothelial cell culture additive + 1% double antibody (containing 10000 U / mL each of penicillin and streptomycin); 37°C, 5% CO2 incubator.

[0152] Preparation of rhododendron, rhododendron derivatives, ferroptosis inducers Erastin and RSL3: Accurately weigh appropriate amounts of rhododendron, rhododendron derivatives, Erastin and RSL3, and prepare them into stock solutions with concentrations of 40mmol / L, 40mmol / L, 10mmol / L, 1mmol / L and 1mmol / L, respectively, using dimethyl sulfoxide (DMSO). Dilute them to the required concentration using blank ECM culture medium before use.

[0153] MTT method was used to determine the inhibitory activity of rhododendron and rhododendron derivatives on erastin and RSL3-induced HUVEC cell ferroptosis: HUVEC cells in the logarithmic growth phase were inoculated in 96-well plates for culture. After the cells adhered to the wall, the following treatments were performed: 1. Erastin-induced ferroptosis screening model: control group, model group (Erastin 5μmol / L), Erastin + rhododendron derivative (10μmol / L) group, Erastin + rhododendron (10μmol / L) group; 2. RSL3-induced ferroptosis screening model: control group, model group (RSL31μmol / L), RSL3 + rhododendron derivative (10μmol / L) group, RSL3 + rhododendron (10μmol / L) group; 3 replicates were set for each compound. After 24h and 12h of treatment, 10μL of MTT solution was added to each well and cultured for 4h. The absorbance at 490 nm was measured by an enzyme-labeled instrument, and the cell survival rate (%) was calculated using the following formula: A experimental group / A control group×100%.

[0154] 3. Experimental results

[0155] Effects of rhododendronin and rhododendronin derivatives on the survival rate of HUVEC cells induced by erastin and RSL3, respectively. Figure 1 A and B in.

[0156] The results are as follows Figure 1 As shown in A and B in the figure, some of the compounds synthesized by the present invention (rhododendron derivatives B3, F3, G2, G3) showed significant inhibitory effects on cell ferroptosis in the HUVEC cell ferroptosis model induced by Erastin and RSL3, respectively. Among them, rhododendron derivative G3 showed better inhibitory effects on cell ferroptosis than rhododendron in the HUVEC cell ferroptosis model induced by Erastin and RSL3, and its inhibitory effects on cell ferroptosis were particularly significant. 50 They are 2.027 and 1.484 μmol / L respectively.

[0157] Figure 2 This indicates that the inhibition of Erastin-induced HUVEC cell ferroptosis by rhododendrin derivative G3 increases with increasing concentration, and EC 50It is 2.027μmol / L.

[0158] Figure 3 It is shown that the inhibition of RSL3-induced HUVEC cell ferroptosis by rhododendrin derivative G3 is enhanced with the increase of concentration, and EC 50 It is 1.484μmol / L.

[0159] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0160] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A rhododendron derivative, wherein the rhododendron derivative has a structure as shown in the general formula (I): in, R1 is selected from Any of the following: R2 is selected from Any one of; n is an integer from 1 to 8.

2. The rhododendronine derivative according to claim 2, characterized in that The rhododendron derivative is any one of the following compounds:

3. The method for preparing a rhododendronine derivative according to claim 2, characterized in that: include: Intermediate 3, intermediate 4, boric acid, L-proline and magnesium oxide are added to glycerol, mixed and heated to 105-115° C. for reaction, and a reaction product is obtained after the reaction is completed. The reaction product is separated and purified to obtain a rhododendronine derivative; The structural formula of the intermediate 3 is as follows: The general structural formula of the intermediate 4 is as follows: Wherein R3 is selected from Any of the following: R4 is selected from Any one of; n is 2 or 3.

4. The preparation method according to claim 3, characterized in that: The molar ratio of the intermediate 3, the intermediate 4, boric acid, L-proline and magnesium oxide is 0.5-1.5:3.5-4.5:2.5-3.5:0.5-1.5:1.5-2.5; the volume of the glycerol is 0.5-1.5 mL.

5. The preparation method according to claim 3, characterized in that: The reaction time is 3-7h.

6. The preparation method according to claim 3, characterized in that: The separation and purification comprises: using ethanol to dissolve the reaction product, then adding silica gel to mix the sample, then drying under reduced pressure, silica gel column chromatography, then eluting with an eluent to obtain a liquid, and drying the liquid under reduced pressure to obtain a solid powder, namely the rhododendron derivative.

7. Use of rhododendrin or rhododendrin structural analogs in the preparation of vascular endothelial cell ferroptosis inhibitors, characterized in that: The rhododendron structural analogs include the rhododendron derivatives according to claim 1 and stereoisomers of the rhododendron derivatives.

8. Use of rhododendron or rhododendron structural analogs in the preparation of a drug for preventing or treating ferroptosis-related cardiovascular diseases, characterized in that: The rhododendron structural analogs include the rhododendron derivatives according to claim 1 and stereoisomers of the rhododendron derivatives.

9. The use according to claim 8, wherein the ferroptosis-related cardiovascular diseases include: Atherosclerosis, hypertension, coronary artery disease, peripheral arterial disease, heart failure, diabetes mellitus, and chronic renal failure.

Citation Information

Patent Citations

  • Pinocembrin synthesis method

    CN106220601A